Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fespixon Cream for Diabetic Foot Ulcers (TEXAS 3A, 3B)
NCT05438251Phase 4Terminated
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Botanical drug
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Fespixon in diabetic foot ulcer (DFU), sponsored by Oneness Biotech Co., Ltd. Primary endpoints: Incidence of the grade down of the target ulcer at 12 weeks and Time to the ulcer grade down at 12 weeks. Started Aug 2022; status: terminated.
02
Drugs
Fespixon
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT05438251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438251.